Search Results
Your search for all items matches 33990 pages
Showing 201 - 250PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
LEAP-012: Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma
The combination of the VEGF tyrosine kinase inhibitor lenvatinib, the PD-1 inhibitor pembrolizumab, and transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma (HCC) compared with TACE alone, according to...
AI Language Models May Generate Effective Physician's Letters
An artificial intelligence (AI) algorithm may be effective at writing physician’s letters, according to a recent study published by Heilmeyer et al in JMIR Medical Informatics. Background According to recent surveys, physicians may spend almost 3 hours per day on documentation activities. “The...
ChatGPT May Demonstrate Human-Level Assessment of Brain Tumor MRI Reports
In the field of radiology, where a correct diagnosis is critical to ensure proper patient care, large language models such as ChatGPT may improve accuracy or offer a second opinion in assessing brain tumor magnetic response imaging (MRI) reports, according to a recent study published by Mitsuyama...
DESTINY-Breast12: T-DXd of Benefit in Patients With Breast Cancer and Brain Metastases
Late-breaking findings from the phase IIIb/IV, open-label DESTINY-Breast12 trial support the use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive metastatic breast cancer and brain metastases who have experienced disease progression on at least...
‘Encouraging’ Pathologic Responses Achieved With Novel Combination Regimen in Early-Stage NSCLC
In the multiarm phase II NeoCOAST-2 trial, neoadjuvant treatment with datopotamab deruxtecan (Dato-DXd) plus the monoclonal antibody durvalumab and single-agent platinum chemotherapy led to promising rates of pathologic complete and major pathologic responses in patients with early-stage non–small...
NO-CUT Trial: Nonoperative Management of Benefit for Many Patients With Rectal Cancer
Total neoadjuvant therapy (TNT) followed by rectal surgery is the standard of care in proficient mismatch repair (pMMR) locally advanced rectal cancer, but studies are finding that patients with clinical complete response may often avoid surgery and be followed “nonoperatively.” In the first...
Novel Radioconjugate or Conventional Care Prior to Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory AML
As reported in Journal of Clinical Oncology by Gyurkocza et al, the phase III SIERRA trial has shown higher rates of durable complete remissions with the anti-CD45 radioconjugate iodine-131–apamistamab vs conventional care followed by allogeneic hematopoietic cell transplantation (allo-HCT) in...
Atezolizumab Plus Platinum Doublet and Maintenance Niraparib for Late-Relapsing Recurrent Ovarian Cancer
As reported in the Journal of Clinical Oncology by González-Martín et al, a phase III trial (ENGOT-OV41/GEICO 69-O/ANITA) has shown no progression-free survival benefit with the addition of atezolizumab to a carboplatin doublet and maintenance niraparib in patients with recurrent ovarian cancer...
Spiritual Themes, Distrust May Factor Into Black Patients’ Reluctance to Participate in Cancer Clinical Trials
Spiritual beliefs and a historically based distrust of clinical research may influence Black patients’ decisions about whether to participate in cancer trials, according to new findings presented by Gomez et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract...
Radiopharmaceutical Therapy May Offer Benefit in Patients With Refractory Meningioma
A radiopharmaceutical therapy has demonstrated early efficacy in patients with difficult-to-treat meningioma, according to new findings presented by Merrell et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 2) and simultaneously published in the...
Certain KRAS Gene Mutations Linked to Improved Prognosis in Pancreatic Cancer
A common mutation in the KRAS gene seems to be associated with improved overall survival in pancreatic ductal adenocarcinoma compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a recent study published in...
FDA Approves Perioperative Nivolumab for Resectable NSCLC
On October 3, 2024, the U.S. Food and Drug Administration approved nivolumab (Opdivo) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors ≥ 4 cm and/or node-positive) non–small cell...
Autologous vs Allogeneic Stem Cell Transplantation in Younger Patients With Peripheral T-Cell Lymphoma: 7-Year Follow-up
In an analysis reported in the Journal of Clinical Oncology, Tournilhac et al identified 7-year outcomes of the phase III AATT trial evaluating autologous vs allogeneic transplantation in younger patients with peripheral T-cell lymphoma. Study Details In the trial, 103 patients (aged 18–60) from...
Strategies for Recovering Neurocognitive Function After Cranial Radiation Therapy
A substantial number of patients with brain metastases who experience cognitive side effects after radiation therapy may fully regain cognitive function, according to recent findings presented by Cherng et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 150). ...
Conversations on Cancer: Exploring Religious Literacy and Spirituality in Cancer Care
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team, ...
Duration of Postmastectomy Radiation Therapy in Patients Planning Breast Reconstruction
An accelerated course of postmastectomy radiation therapy may not increase complications in patients with breast cancer undergoing breast reconstruction, according to recent findings presented by Poppe et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 1) and ...
Adjuvant Nivolumab vs Placebo in Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy
As reported in the Journal of Clinical Oncology by Motzer et al, part B of the phase III CheckMate 914 trial showed no disease-free survival benefit with the adjuvant use of nivolumab vs placebo in patients with localized renal cell carcinoma at high risk of recurrence after nephrectomy. These...
Distinguished Service Awards Presented at the IASLC World Conference on Lung Cancer
Distinguished Service Awards were presented to Kwun Fong, MBBS, PhD, FRACP; Claudia Henschke, MD, PhD; Erik Thunnissen, MD, PhD; and Julie Brahmer, MD, MSc, FASCO, during the 2024 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer. Adi F. Gazdar IASLC...
Navigating Uncharted Waters in the Post-Chevron Sea Change
It is not often that the oncology community looks to the Supreme Court to forecast its future. In 2024, two decisions seemingly unrelated to health care were issued that are likely to have a monumental impact on oncology care delivery. The Court’s rulings—on June 28, Loper Bright Enterprises et ...
HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, confirms the benefit for the STRIDE regimen of the monoclonal antibodies durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.1 [The STRIDE regimen consists of a single priming dose of...
ACS Report: Despite Overall Decreases in Breast Cancer Mortality, Incidence Rising in Key Groups
The American Cancer Society (ACS) recently released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States. The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately...
Radiotherapy vs Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
As reported in the Journal of Clinical Oncology by Nichols et al, final results of the phase II ORATOR trial indicate some differences in toxicity and quality of life between radiotherapy and transoral robotic surgery for oropharyngeal squamous cell carcinoma, with both approaches yielding similar...
LuPSMA vs Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
As reported in The Lancet by Morris et al, the phase III PSMAfore trial has shown improved progression-free survival with lutetium-177–labeled PSMA-617 (LuPSMA) vs change in androgen receptor pathway inhibitor (ARPI) in taxane-naive patients with metastatic castration-resistant prostate cancer...
Addition of Nivolumab to Tivozanib Following Immune Checkpoint Inhibitor Treatment in Metastatic Renal Cell Carcinoma
As reported in The Lancet by Choueiri et al, the phase III TiNivo-2 trial has shown that immune checkpoint inhibitor rechallenge with nivolumab plus tivozanib did not improve progression-free survival vs tivozanib alone in patients with metastatic renal cell carcinoma following immune checkpoint...
Standard Chemoradiation May Be Superior to Deintensification Approaches in Patients With HPV-Associated Oropharyngeal Cancer
Deintensified treatment involving a lower radiation dose and immunotherapy in place of chemotherapy may not perform as well as a more rigorous chemoradiation treatment approach in patients with early-stage human papillomavirus (HPV)-associated oropharyngeal cancer, according to new findings...
Intensity-Modulated Radiation Therapy and Proton-Beam Therapy May Offer Equally High Quality of Life and Tumor Control in Patients With Localized Prostate Cancer
Two types of contemporary radiation therapy—proton-beam therapy or intensity-modulated radiation therapy—may provide comparable rates of tumor control with no differences in patient-reported quality of life among patients with low- and intermediate-risk prostate cancer, according to new findings...
Immunotherapy/Chemoradiotherapy for Patients With Limited-Stage Small Cell Lung Cancer
Findings of a multi-institutional phase III trial indicated that people with limited-stage small cell lung cancer may benefit from the addition of immunotherapy to chemoradiotherapy, but not if both treatments are given simultaneously, new research finds. The results suggest that the timing of when ...
KEYNOTE-671: Overall Survival With Perioperative Pembrolizumab in Resectable NSCLC
As reported in The Lancet by Spicer et al, overall survival results of the phase III KEYNOTE-671 trial indicate benefit of the addition of neoadjuvant pembrolizumab to chemotherapy followed by adjuvant pembrolizumab in patients with early-stage non–small cell lung cancer (NSCLC). At the first...
Adding Durvalumab to Neoadjuvant Regimen Improves Pathologic Complete Response Rate in High-Risk Breast Cancer
Adding the immune checkpoint inhibitor durvalumab, with or without the monoclonal antibody oleclumab, to neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) significantly improved pathologic complete response rates in patients with high-risk hormone receptor (HR)-positive breast ...
EMBER: Imlunestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
In the the phase IA/B dose-escalation and -expansion EMBER study reported in the Journal of Clinical Oncology by Jhaveri et al, the next-generation oral selective estrogen receptor degrader imlunestrant (alone and in combination with other targeted therapies) demonstrated a manageable safety...
Cancer and Cancer-Related Therapy May Increase Cardiovascular Disease Risk in Older Cancer Survivors
Investigators have uncovered a higher risk for strokes, heart attacks, and hospital admissions for heart failure in older cancer survivors, according to a recent study published by Muhandiramge et al in Cancer. Background Although advances in cancer treatment have led to decreased mortality rates...
Pharmaceutical Industry Sponsors and Clinical Cancer Research in the United States
Investigators have identified a substantial increase in the proportion of U.S. patients with cancer participating in clinical trials sponsored by the pharmaceutical industry over the past decade compared with those supported by the federal government, according to findings recently presented by...
Creating a Culture of Diversity, Equity, and Inclusion: Why It Matters Clinically and Ethically
The National Comprehensive Cancer Network (NCCN) has always prided itself on its commitment to evidence-based, expert consensus–driven recommendations for cancer care, with a special focus on breaking down the barriers that contribute to disparities in outcomes across all patients with cancer. With ...
Amivantamab-vmjw Plus Lazertinib Improves Long-Term Outcomes in First-Line Setting of EGFR-Mutant Advanced NSCLC
The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
Updated Findings With Belzutifan in von Hippel-Lindau Disease–Associated CNS Hemangioblastomas
As reported in The Lancet Oncology by Iliopoulos et al, updated findings from the phase II LITESPARK-004 trial support the efficacy of belzutifan in patients with von Hippel-Lindau (VHL) disease–associated CNS hemangioblastomas. Study Details In the study, 50 patients with CNS hemangioblastomas...
Impact of Whole-Lung Irradiation in Newly Diagnosed Rhabdomyosarcoma With Lung Metastases
In a retrospective analysis from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group (COG) reported in the Journal of Clinical Oncology, Luo et al found that whole-lung irradiation (WLI) was associated with significantly better event-free survival vs no WLI in patients with newly...
Quality Improvements in Lung Cancer Surgery and Tumor Pathology May Extend Survival Postsurgery
Advancing surgical and pathologic techniques may improve overall survival rates in high-risk patients with lung cancer, according to new findings presented by Akinbobola et al at the 2024 ASCO Quality Care Symposium (Abstract 278). Background “Over the past 15 years, a quality improvement...
Conversations Between Physicians and Older Patients About Physical Activity May Reduce Falls During Cancer Treatment
Communication between health-care providers and older patients with cancer regarding the significance of physical activity may help reduce the risk of falls during cancer therapy, according to new findings presented by Lu and Zheng at the 2024 ASCO Quality Care Symposium (Abstract 224). Background...
FDA Approves Selpercatinib for RET Fusion–Positive Medullary Thyroid Cancer
On September 27, 2024, the U.S. Food and Drug Administration granted traditional approval to selpercatinib (Retevmo) for adult and pediatric patients aged 2 years and older with advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved test, who require...
CABINET Trial Supports Multitargeted Tyrosine Kinase Inhibitor for Advanced Neuroendocrine Tumors
As reported in The New England Journal of Medicine by Chan et al, the multicenter phase III CABINET trial has shown significantly improved progression-free survival with the multitargeted tyrosine kinase inhibitor cabozantinib vs a placebo in previously treated patients with progressive, advanced...
Community-Academic Partnership May Successfully Reduce Radon-Related Lung Cancer Risk in Native Population
A community and academic partnership may provide effective education about the risks of radon, testing for radon, mitigating radon in homes with high levels of the chemical, and reducing the risk of developing lung cancer among Native community members residing in Wisconsin, according to new...
Olanzapine May Reduce Chemotherapy-Induced Nausea and Improve Quality of Life Among Patients With Cancer
Researchers have found that olanzapine may be more effective in controlling severe nausea and improving the quality of life in patients with cancer who are undergoing treatment with chemotherapy, according to new findings presented by Peppone et al at the 2024 ASCO Quality Care Symposium (Abstract...
Datopotamab Deruxtecan vs Docetaxel in Previously Treated Advanced or Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Ahn et al, the phase III TROPION-Lung01 trial showed significantly improved progression-free survival—but not overall survival—with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel in patients with...
Overall Survival Results With Pembrolizumab and Chemoradiotherapy in Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
As reported in The Lancet by Lorusso et al, overall survival results from the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial indicated a significant benefit of pembrolizumab vs placebo with concurrent chemoradiotherapy followed by pembrolizumab vs placebo in patients with newly diagnosed,...
Quality-of-Life Outcomes: Whole-Breast Irradiation vs Accelerated Partial-Breast Irradiation Following Breast-Conserving Surgery
A study by Ganz et al assessed quality-of-life outcomes following whole- or partial-breast radiation in patients with breast cancer who underwent lumpectomy. The researchers published their findings in the Journal of the National Cancer Institute. Study Methods and Results In the NRG Oncology...
Neighborhood Environment May Be Linked to Prostate Cancer Risk in Men With West African Genetic Ancestry
West African genetic ancestry may be associated with an increased risk of prostate cancer among men residing in disadvantaged neighborhoods but not among those residing in more affluent neighborhoods, according to a recent study published by Pichardo et al in JAMA Network Open. The findings...
More Than Half of AYA Cancer Survivors Experience Financial Toxicity and Are Unable to Afford Food and Housing
A study conducted by Kaitlyn Lapen, MD, a radiation oncologist resident at Memorial Sloan Kettering Cancer Center, and colleagues evaluated the financial challenges adolescent and young adults (AYA) survivors experience during and after treatment. They found that more than half (54%) of these...
AYAs Enrolled in a Cancer Program Were More Likely to Receive Guideline-Recommended Care
A retrospective study of AYA patients with cancer enrolled in the University of North Carolina (UNC) at Chapel Hill’s AYA Cancer Program, which aims to address these challenges, were more likely to receive guideline-recommended care, including clinical trial enrollment, fertility counseling, and...
FDA Approves Osimertinib in Stage III NSCLC After Chemoradiotherapy
On September 25, the U.S. Food and Drug Administration approved osimertinib (Tagrisso) for adults with locally advanced, unresectable (stage III) non–small cell lung cancer (NSCLC) whose disease has not progressed during or after concurrent or sequential platinum-based chemoradiation therapy. These ...
